Physician profile
David Steven Silvers
NPI 1891739488
$22,513.10
in general payments reported to CMS, 2019-2025
64 companies · $3,289 in 2025
The $3,289 reported for 2025 was more than what 80% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,689 · 2020: $2,387 · 2021: $2,835 · 2022: $3,488 · 2023: $3,456 · 2024: $3,368 · 2025: $3,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,898 · Education: $193 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $22.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,898.30 |
| Education | $192.94 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $22.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $2,961.98 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Abbvie INC. | $1,614.58 | 2021-2025 | Ubrelvy, Qulipta, Skyrizi |
| Teva Pharmaceuticals USA, INC. | $1,283.25 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $954.68 | 2019-2025 | Ingrezza, Ongentys |
| Lilly USA, LLC | $854.14 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Harmony Biosciences LLC | $848.26 | 2020-2025 | Wakix |
| Mdd US Operations, LLC | $814.92 | 2019-2025 | Apokyn, Apokyn |
| Neurelis, INC. | $813.47 | 2020-2025 | Valtoco |
| Biogen, INC. | $795.19 | 2019-2025 | Leqembi, Vumerity, Spinraza |
| Ucb, INC. | $759.55 | 2019-2025 | Zilbrysq, Briviact, Rystiggo |
| Acorda Therapeutics, INC | $690.76 | 2019-2024 | Inbrija, Ampyra |
| Kyowa Kirin, INC. | $687.30 | 2019-2025 | Nourianz |
| Pfizer INC. | $622.83 | 2023-2025 | |
| Sk Life Science, INC. | $621.66 | 2021-2025 | Xcopri |
| Argenx US, INC. | $485.62 | 2022-2024 | Vyvgart Hytrulo, Vyvgart |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Upsher-Smith Laboratories LLC | $461.02 | 2020-2023 | |
| Alexion Pharmaceuticals, INC. | $450.30 | 2021-2025 | Ultomiris, Soliris |
| Adamas Pharmaceuticals, INC. | $433.56 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $416.59 | 2020-2022 | |
| Lundbeck LLC | $405.50 | 2019-2025 | Vyepti |
| Tanabe Pharma America, INC. | $387.04 | 2021-2025 | Radicava |
| Amgen INC. | $356.84 | 2019-2025 | Uplizna |
| Otsuka America Pharmaceutical, INC. | $354.96 | 2023-2025 | Rexulti, Nuedexta |
| Genzyme Corporation | $335.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $318.68 | 2019-2024 | |
| Emd Serono, INC. | $285.12 | 2019-2024 | Mavenclad |
| Biohaven Pharmaceutical Holding Company LTD. | $282.09 | 2022 | |
| Janssen Biotech, INC. | $239.28 | 2025 | |
| Jazz Pharmaceuticals INC. | $223.97 | 2020-2024 | |
| Allergan, INC. | $202.84 | 2020 | |
| Arbor Pharmaceuticals, INC. | $191.32 | 2019-2022 | |
| Celgene Corporation | $172.53 | 2021-2025 | Zeposia |
| Biohaven Pharmaceuticals, INC. | $153.97 | 2020-2021 | |
| Merz Pharmaceuticals, LLC | $153.18 | 2023-2025 | Xeomin, Inbrija |
| Bausch Health US, LLC | $146.21 | 2019-2020 | |
| Genentech USA, INC. | $138.01 | 2022-2025 | Evrysdi, Ocrevus Zunovo |
| Acadia Pharmaceuticals INC | $124.52 | 2019-2021 | |
| Axsome Therapeutics, INC. | $116.95 | 2024-2025 | Symbravo, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $114.89 | 2022-2024 | Hyqvia |
| Janssen Pharmaceuticals, INC | $113.18 | 2020-2022 | |
| Boston Scientific Corporation | $92.71 | 2021-2024 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $85.87 | 2020-2023 | Zeposia |
| Cala Health, INC. | $76.59 | 2022-2024 | Cala Trio, Cala Kiq |
| Almatica Pharma LLC | $75.33 | 2021-2023 | Gralise |
| C2n Diagnostics, LLC | $75.09 | 2025 | Precivityad2 |
| Idorsia Pharmaceuticals US INC | $69.08 | 2023-2024 | Quviviq |
| Avion Pharmaceuticals | $66.40 | 2022-2023 | Dhivy |
| Ani Pharmaceuticals, INC. | $65.94 | 2024-2025 | Purified Cortrophin Gel |
| Alnylam Pharmaceuticals INC. | $55.68 | 2022-2023 | Onpattro |
| Vanda Pharmaceuticals INC. | $55.10 | 2024-2025 | Ponvory |
| Catalyst Pharmaceuticals, INC. | $49.95 | 2022-2023 | Firdapse |
| Azurity Pharmaceuticals, INC. | $48.83 | 2023-2024 | Horizant, Horizant |
| Akcea Therapeutics, INC. | $44.76 | 2020-2021 | |
| Inspire Medical Systems, INC. | $40.28 | 2024 | Inspire |
| Microtransponder, INC. | $32.71 | 2024 | |
| Insightec,INC | $26.94 | 2023 | Exablate |
| Dynasplint Systems INC. | $24.61 | 2024 | Dynasplint |
| Abbott Laboratories | $24.07 | 2024 | Infinity |
| Eisai INC. | $22.40 | 2022 | |
| Averitas Pharma INC. | $21.55 | 2025 | Qutenza |
| Tms Neurohealth Centers INC. | $20.65 | 2025 | Tms Neurohealth Centers INC. |
| Ultragenyx Pharmaceutical INC. | $18.36 | 2022 | |
| Zyla Life Sciences, INC. | $17.80 | 2020 | |
| Impel Pharmaceuticals INC. | $16.25 | 2023 | Trudhesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Silvers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.